Peter S. Linsley mainly investigates Cell biology, T cell, CD28, Immunology and Molecular biology. His research integrates issues of Cell, Receptor, RNA interference, microRNA and Gene silencing in his study of Cell biology. Peter S. Linsley has included themes like B-cell receptor and CD80, CD40 in his T cell study.
His CD28 research includes themes of T lymphocyte and Antigen presentation. His Molecular biology research focuses on Transfection and how it connects with Vector, Recombinant DNA, Phenotype and Cell growth. His research in Antigen-presenting cell tackles topics such as IL-2 receptor which are related to areas like Interleukin 21.
His primary areas of study are Molecular biology, T cell, Antigen, Immunology and CD28. Peter S. Linsley combines subjects such as Cytotoxic T cell, Receptor and Cell biology with his study of T cell. His study in Cell biology is interdisciplinary in nature, drawing from both Gene silencing, microRNA, RNA interference and Transfection.
The Antigen study which covers Monoclonal antibody that intersects with Lung. His biological study spans a wide range of topics, including In vivo, Blockade and Transplantation. His studies deal with areas such as T lymphocyte, CD80, CD40, Major histocompatibility complex and Antigen presentation as well as CD28.
MicroRNA, RNA interference, Small interfering RNA, Gene silencing and Cell biology are his primary areas of study. The concepts of his microRNA study are interwoven with issues in Cancer research, Phenotype, Carcinogenesis, Messenger RNA and Cell cycle. His research investigates the link between RNA interference and topics such as Genetic screen that cross with problems in Suicide gene.
His Trans-acting siRNA study in the realm of Small interfering RNA interacts with subjects such as Midbody. His work deals with themes such as Endoreduplication, Molecular biology and Gene expression profiling, which intersect with Cell biology. Specifically, his work in Antigen is concerned with the study of CD28.
Peter S. Linsley mainly focuses on microRNA, Cell biology, RNA interference, Gene silencing and Small interfering RNA. His microRNA research integrates issues from Cancer research, Gene expression, Carcinogenesis, Downregulation and upregulation and Cell cycle. His research in Cell biology intersects with topics in Myeloid, Transfection, Molecular biology, Messenger RNA and Autoimmunity.
His Molecular biology study incorporates themes from CD3 and Phosphorylation. His Gene silencing study necessitates a more in-depth grasp of Genetics. His studies in Small interfering RNA integrate themes in fields like Small hairpin RNA, RNA silencing and Bioinformatics.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Gene expression profiling predicts clinical outcome of breast cancer
Laura J. van 't Veer;Hongyue Dai;Marc J. van de Vijver;Yudong D. He.
Nature (2002)
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lee P. Lim;Nelson C. Lau;Philip Garrett-Engele;Andrew Grimson.
Nature (2005)
A microRNA component of the p53 tumour suppressor network
Lin He;Xingyue He;Xingyue He;Lee P. Lim;Elisa de Stanchina;Elisa de Stanchina.
Nature (2007)
Expression profiling reveals off-target gene regulation by RNAi
Aimee L Jackson;Steven R Bartz;Janell Schelter;Sumire V Kobayashi.
Nature Biotechnology (2003)
CTLA-4 can function as a negative regulator of T cell activation
Theresa L. Walunas;Deborah J. Lenschow;Christina Y. Bakker;Peter S. Linsley.
Immunity (1994)
CTLA-4 is a second receptor for the B cell activation antigen B7.
Peter S. Linsley;William Brady;Mark Urnes;Laura S. Grosmaire.
Journal of Experimental Medicine (1991)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
Richard V. Parry;Jens M. Chemnitz;Kenneth A. Frauwirth;Anthony R. Lanfranco.
Molecular and Cellular Biology (2005)
Genetics of gene expression surveyed in maize, mouse and man
Eric E. Schadt;Stephanie A. Monks;Thomas A. Drake;Aldons J. Lusis.
Nature (2003)
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.
Christian P. Larsen;Eric T. Elwood;Diane Z. Alexander;Shannon C. Ritchie.
Nature (1996)
The role of the CD28 receptor during T cell responses to antigen.
Peter S. Linsley;Jeffrey A. Ledbetter.
Annual Review of Immunology (1993)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Washington
University of Bonn
Bristol-Myers Squibb (Germany)
Seattle Genetics (United States)
Emory University
Bonum Therapeutics
Rutgers, The State University of New Jersey
Yale University
Memorial Sloan Kettering Cancer Center
Sage Bionetworks
University at Buffalo, State University of New York
University of Chicago
University of Rhode Island
Polytechnic University of Turin
National Institute of Standards and Technology
Tsinghua University
Bournemouth University
University of Exeter
University of Brasília
Norwich Research Park
University of Cambridge
University of Barcelona
Texas A&M University
Chinese Academy of Sciences
University of Lethbridge
Technical University of Munich